Last reviewed · How we verify
Pitocin Injectable Product
At a glance
| Generic name | Pitocin Injectable Product |
|---|---|
| Also known as | Synthetic Oxytocin |
| Sponsor | Rambam Health Care Campus |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Intra-Umbilical Vein Oxytocin Injection as an Adjunct to Active Management of the Third Stage of Labour (NA)
- Carbetocin vs Misoprostol for Postpartum Hemorrhage Prevention (NA)
- Comparing High Versus Low Dose of Oxytocin, in Gravida Women With BMI 30 and Above Which Are Undergoing Induction of Labor (PHASE4)
- TRAnexamic Acid for Preventing Blood Loss Following a Cesarean Delivery in Women With Placenta pREVIA (PHASE3)
- Oxytocin in Multiparous Women (NA)
- Methods Decreasing Bleeding in Open Myomectomy (PHASE4)
- Comparison Of The Effects Of Carbetocin And Oxytocin In C-Sectıon (PHASE4)
- Carbetocin Versus Oxytocin for the Prevention of Postpartum Hemorrhage in Emergency Caesarean Delivery (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pitocin Injectable Product CI brief — competitive landscape report
- Pitocin Injectable Product updates RSS · CI watch RSS
- Rambam Health Care Campus portfolio CI